Dr. Obeid is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
333 Cottman Ave
Departmet of Clinical Genetics
Philadelphia, PA 19111Phone+1 215-728-2791Fax+1 215-214-3779
Education & Training
- University of ChicagoFellowship, Hematology and Medical Oncology, 2009 - 2013
- Yale-New Haven Medical CenterResidency, Internal Medicine, 2001 - 2004
- American University of Beirut Faculty of MedicineClass of 2000
Certifications & Licensure
- NJ State Medical License 2022 - 2025
- PA State Medical License 2013 - 2024
- IL State Medical License 2009 - 2014
- CT State Medical License 2004 - 2010
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Start of enrollment: 2016 May 31
- A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study Start of enrollment: 2020 Jun 10
Publications & Presentations
PubMed
- What Proportion of BRCA-Associated Breast Cancer Is Human Epidermal Growth Factor 2-Low and Eligible for Additional Targeted Therapy?Emily Forester, Aakash Belsare, Dong Won Kim, Kristen Whitaker, Elias Obeid
The Journal of Surgical Research. 2024-07-01 - Clinical characteristics, treatment patterns, and outcomes in adult patients with germline-mutated, HER2-negative advanced breast cancer: a retrospective medical recor...Elias Obeid, Rohan C Parikh, Elizabeth Esterberg, Bhakti Arondekar, Abigail Hitchens
Frontiers in Oncology. 2024-01-01 - 8 citationsA phase 1 study of nivolumab in combination with interferon-gamma for patients with advanced solid tumors.Matthew Zibelman, Alexander W MacFarlane 4th, Kimberly Costello, Thomas McGowan, John O'Neill
Nature Communications. 2023-07-27
Press Mentions
- 'Patients Are Going to Ask for It': Inside Ochsner's Pharmacogenomic Testing ProgramSeptember 9th, 2024
- HMH, St. Joseph’s Open Cancer Center of TotowaMay 26th, 2023
- St. Joseph’s Health and Hackensack Meridian Health Open Comprehensive Cancer Center at TotowaMay 25th, 2023
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: